Topical clindamycin in the management of acne vulgaris

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 15, 2007, Pages 2625-2664

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

Acne vulgaris; Antimicrobial; Clindamycin; Inflammation; Topical administration

Indexed keywords

ADAPALENE; AZELAIC ACID; AZITHROMYCIN; BENZACLIN; BENZOYL PEROXIDE; CLARITHROMYCIN; CLINDAGEL; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CLINDAMYCIN PLUS RETINOIC ACID; COTRIMOXAZOLE; DAPSONE; DOXYCYCLINE; DUAC; ERYTHROMYCIN; ISOTRETINOIN; LINCOMYCIN; MINOCYCLINE; NICOTINAMIDE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RETINOIC ACID; RETINOID; SULFACETAMIDE; TAZAROTENE; TETRACYCLINE; UNCLASSIFIED DRUG; ZIANA; ZINC; ZINC ACETATE;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; APPLICATION SITE REACTION; ARTICLE; BACTERIAL GROWTH; BLEACHING; BURNING SENSATION; CLINICAL PRACTICE; CLINICAL TRIAL; CLOSTRIDIUM; COMBINATION CHEMOTHERAPY; CONTACT DERMATITIS; CORYNEBACTERIUM; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EPIGASTRIC PAIN; ERYTHEMA; EXFOLIATIVE DERMATITIS; FOOD AND DRUG ADMINISTRATION; GEL; GROWTH INHIBITION; HAND WASHING; HUMAN; INFECTION CONTROL; LOTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PATIENT CARE; PHOTODYNAMIC THERAPY; PROPIONIBACTERIUM ACNES; PROPIONIBACTERIUM GRANULOSUM; PRURITUS; PSEUDOMEMBRANOUS COLITIS; SIDE EFFECT; SKIN ABRASION; SKIN IRRITATION; STAPHYLOCOCCUS; STREPTOCOCCUS; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DISEASE MANAGEMENT; HUMANS;

EID: 35648951759     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.15.2625     Document Type: Article

References (110)

1. STERN S: Medication and medical service utilization for acne 1995-1998. J. Am. Acad. Dermatol. (2000) 43:1042-1048.
2. SCHEINFELD NS: Acne: a review of diagnosis and treatment. P&T(2007) 32:340-347.
3. PURVIS D, ROBINSON E, MERRY S, WATSON P: Acne, anxiety, depression, and suicide in teenagers: a cross-sectional survey of New Zealand secondary school students. J. Paediatr. Child Health (2006) 42:793-796.
4. WILLIAMS C, LAYTON AM: Persistent acne in women: implications for the patient and therapy. Am. J. Clin. Dermatol., (2006) 7:281-290.
5. HAIDER A, SHAW JC: Treatment of acne vulgaris. JAMA (2004) 292:726-735.
6. GOLNICK H, CUNLIFFE W, BERSON D et al.: Management of acne: a report from the global alliance to improve outcomes in acne. J. Am. Acad. Dermatol. (2003) 49(1 Suppl.):S1-S37.
7. RAO S, MALIK MA, WILDER L: What is the best treatment for mild to moderate acne? J. Fam. Prac. (2006) 55:994, 996.
8. Aczone® (dapsone, topical) product information. Astellas Pharma, Fort Collins, CO, July (2005).
9. GUAY DRP: Update on clindamycin in the management of bacterial, fungal, and protozoal infections. Expert Opin. Pharmacother. (2007) 8(14):2401-2444.
10. WEBSTER GF, LEYDEN JJ, MCGINLEY KJ, MCARTHUR WP: Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob. Agents Chemother. (1982) 21:770-772.
11. WEBSTER GF, MCGINLEY KJ, LEYDEN JJ: Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br. J. Dermatol. (1981) 104:453-457.
12. AKAMATSU H, NISHIJIMA. S, TAKAHASHI M, USHIJIMA T. ASADA Y: Effects of subminimal inhibitory concentrations of erythromycin, tetracycline, clindamycin, and minocycline on the neutrophil chemotactic factor production in Propionibacterium acnes biotypes 1-5. J. Dermatol (1991) 18:247-251.
13. LEYDEN JJ, MCGINLEY K, MILLS OH, KLIGMAN AM: Topical antibiotics and topical antimicrobial agents in acne therapy. Acta Dermatovenereol. (1980) Suppl. 89:75-82.
14. AMR S, BROWN MB, MARTIN GP, FORBES B: Activation of clindamycin phosphate by human skin. J. Appl. Microbiol. (2001) 90:550-554.
15. VAN HOOGDALEM EJ: Transdermal absorption of topical anti-acne agents in man: review of clinical pharmacokinetic data. J. Eur. Acad. Dermatol. Venereol. (1998) 11(Suppl. 1):S13-S19.
16. SIEGLE RJ, FEKETY R, SARBONE PD, FINCH RN, DEERY HG, VOORHEES JJ: Effects of topical clindamycin on intestinal microflora in patients with acne. J. Am. Acad. Dermatol. (1986) 15:180-185.
17. BORGLUND E, HAGERMARK O, NORD CE: Impact of topical clindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris. Scand. J. Infect. Dis. (1984) 43(Supp1.):76-81.
18. HOFFLER U, KO HL, PULVERER G: Antimicrobial susceptibility of Propionibacterium acnes and related microbial species. Antimicrob. Agents Chemother. (1976) 10:378-394.
19. KUROKAWA I, NISHIJIMA S, ASADA Y: The antibiotic susceptibility of Propionibacterium acnes: a 15-year bacteriological study and retrospective evaluation. J. Dermatol. (1988) 15:149-154.
20. WANG WLL, EVERETT ED, JOHNSON M, DEAN E: Susceptibility of Propionibacterium acnes to seventeen antibiotics. Antimicrob. Agents Chemotber. (1977) 11:171-173.
21. BROWN JM, POSTON SM: Resistance of propionibacteria to antibiotics used in the treatment of acne. J. Med. Microbiol. (1983) 16:271-280.
22. LEYDEN JJ, MCGINLEY KJ, CAVALIERI S, WEBSTER GF, MILLS OH, KLIGMAN AM: Propionibacterium acnes resistance to antibiotics in acne patients. J. Am. Acad. Dermatol. (1983) 8:41-45.
23. EADY EA, COVE JH, HOLLAND KT. CUNLIFFE WJ: Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br. J. Dermatol. (1989) 121:51-57.
24. EADY EA, JONES CE, TIPPER JL, COVE JH, CUNLIFFE WJ, LAYTON AM: Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ (1993) 306:555-556.
25. NISHIJIMA S, AKAMATSU H, AKAMATSU M, KUROKAWA I, ASADA Y. The antibiotic susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne. J Dermatol. (1994) 21:166-171.
26. OAKLEY A, RADEMAKER M, DUFFILL M, LONG R, SHEWAN J: Propionibacterium: resistance of acne to antibiotics. NZ Med. J. (1995) 108:43-44 (Letter).
27. NISHIJIMA S, KUROKAWA I, KAWABATA S: Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents. J. Int. Med. Res. (1996) 24:473-477.
28. FLUHR JW, GLOOR M, DIETZ P, HOFFLER U: In vitro activity of 6 antimicrobials against propionibacteria isolates from untreated acne papulo-pustulosa. Zent. bl. Bakteriol. (1999) 289:53-61.
29. ROSS JI, SNELLING AM, CARNEGIE E et al.: Antibiotic-resistant acne: lessions from Europe. Br. J. Dermatol.(2003) 148: 467-478.
30. ROSS JI, EADY EA, COVE JH et al.: Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23SrRNA. Antimicrob. Agents Chemother. (1997) 41:1162-1165.
31. NORD CE, OPRICA C; Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe (2006) 12:207-210.
32. SIMONAST T, DRAMAIX M: Treatment of acne with topical antibiotics: lessons from clinical studies. Br. J. Dermatol. (2005) 153:395-403.
33. GANS ER, KLIGMAN AM: Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J. Dermatol. Treat. (2002) 13:107-110.
34. LEYDEN J, LEVY S: The development of antibiotic resistance in Propionibacterium acnes. Cutis (2001) 67(2 Suppl.):21-24.
35. HARKAWAY K, MCGINLEY KJ, FOGLIA AN et al.: Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br. J. Dermatol. (1992) 126:586-590.
36. FRANZ TJ: On the bioavailability of topical formulations of clindamycin hydrochloride. J. Am. Acad. Dermatol. (1983) 9:66-73.
37. KRAUTHEIM A, GOLLNICK H: Transdermal penetration of topical drugs used in the treatment of acne. Clin. Pharmacokinet. (2003) 42:.1287-1304.
38. BARZA M, GOLDSTEIN JA, KANE A, FEINGOLD DS, POCHI PE: Systemic absorption of clindamycin hydrochloride after topical application. J Am. Acad Dermatol. (1982) 7:208-214.
39. LOOKINGBILL DP, CHALKER DK, LINDHOLM JS et al.: Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide get and vehicle gel: combined results of two double-blind investigations. J. Am. Acad. Dermatol. (1997) 37:590-595.
40. ALGRA RJ, ROSEN T, WAISMAN M: Topical clindamycin in acne vulgaris. Safety and stability. Arch. Dermatol. (1977) 113:1390-1391.
41. VORON DA: Systemic absorption of topical clindamycin. Arcb. Dermatol. (1978) 114:798 (Letter).
42. VAN HOOGDALEM EJ, BAVEN TLM, SPIEGEL-MELSEN I, TERPSTRA IJ: Transdermal absorption of clindamycin and tretinoin from topically applied anti-acne formulations in man. Biopharm. Drug Dispos. (1998) 19:563-569.
43. GUIN JD, REYNOLDS R, GIELERAK PL: Penetration of topical clindamycin into comedones. J. Am. Acad Dermatol. (1980) 3:153-156.
44. GUIN JD, LUMMIS WL: Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. J. Am. Acad Dermatol. (1982) 7:265-268.
45. LEVY S: Dermatopharmacology of a new combination gel formulation for the topical treatment of acne. Cutis (2001) 67(2 Suppl.):8-12.
46. CHASSARD D, KANIS R, NAMOUR F, EVENE E, NTSSIKOUSSALABONGUI B, SCHMITZ V: A single centre, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin®) and topical clindamycin lotion (Dalacine® T) in subjects with mild to moderate acne. J. Dermatol. Treat. (2006) 17:154-157.
47. SHALITA AR, MYERS JA et al.; CLINDAMYCIN FOAM STUDY GROUP: The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J. Drugs Dermatol. (2005) 4:48-56.
48. PANZER JD, PANZER JJ: Topical clindamycin in acne: a preliminary study. Cutis (1979) 24:118-119.
49. THOMSEN RJ, STRANIERI A, KNUTSON D, STRAUSS JS: Topical clindamycin treatment of acne. Clinical, surface lipid composition, and quantitative surface microbiology response. Arch. Dermatol. (1980) 116:1031-1034.
50. GUIN JD: Treatment of acne vulgaris with topical clindamycin phosphate: a double-blind study. Int. J. Dermatol. (1981) 20:286-288.
51. KUHLMAN DS, CALLEN JP: A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis (1986) 38:203-206.
52. GUIN JD: Topical clindamycin: a double-blind study comparing clindamycin phosphate with clindamycin hydrochloride. Int. J. Dermatol.(1979) 18:164-166.
53. GOLTZ RW, CORYELL GM, SCHNIEDERS JR, NEIDERT GL: A comparison of Cleocin T® 1 percent solution and Cleocin T® 1 percent lotion in the treatment of acne vulgaris. Cutis (1985) 36:265-268.
54. PARKER F: A comparison of clindamycin 1% solution versus clindamycin 1% get in the treatment of acne vulgaris. Int. J. Dermatol. (1987) 26:121-122.
55. BECKER LE, BERGSTRESSER PR, WHITING DA et al.: Topical clindamycin in acne vulgaris. A cooperative clinical study. Arcb. Dermatol. (1981) 117:482-485.
56. ELLIS CN, GAMMON WR, STONE DZ, HEEZEN-WEHNER JL: A comparison of cleocin T solution, cleocin T gel, and placebo in the treatment of acne vulgaris. Cutis (1988) 42:245-247.
57. MCKENZIE MW, BECK DC, POPOVICH NG: Topical clindamycin formulations for the treatment of acne vulgaris. An evaluation. Arcb. Dermatol. (1981) 117:630-634.
58. ALIREZAI M, GERLACH B, HORVATH A, FORSEA D, BRIANTAIS P, GUYOMAR M: Results of a randomised, multicentre study comparing a new water-based gel of clindamycin 1% versus clindamycin 1% topical solution in the treatment of acne vulgaris. Eur. J. Dermatol (2005) 15:274-278.
59. RIZER RL, SKLAR JL, WHITING D, BUCKO A, SHAVIN J, JARRATT M: Clindamycin phosphate 1% get in acne vulgaris. Adv. Theri (2001) 18:244-252.
60. GOLD MH, RAO J, GOLDMAN MP et al.: A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution. J. Drugs Dermatol. (2005) 4:64-70.
61. CUNLIFFE WJ, FERNANDEZ C, BOJAR R et al.: An observer-blind, parallel-group, randomised, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. J. Dermatol. Treat. (2005) 16:213-218.
62. STOUGHTON RB, CORNELL RC, GANGE RW, WALTER JF: Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis (1980) 26:424, 425, 429.
63. GRATTON D, RAYMOND GP, GUERTIN-LAROCHELLE S et al.: Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J. Am. Acad. Dermatol. (1982) 7:50-53.
64. BRAATHEN LP, Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand J. Infict. Dis. (1984) Suppl. 65:71-75.
65. KATSAMBAS A, TOWARKY AA, STRATIGOS J: Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J. Dermatol. (1987) 116:387-391.
66. SHEEHAN-DARE RA, PAPWORTH-SMITH J, CUNLIFFE WJ: A double-blind comparison of topical clindamycin and oral minocydine in the treatment of acne vulgaris. Acta Derm. Venereol. (1990) 70:534-537.
67. RESH W, STOUGHTON RB: Topically applied antibiotics in acne vulgaris. Clinical response and suppression of Carynebacterium acnes in open comedones. Arcb. Dermatol. (1976) 112:182-184.
68. THOMAS DR, RAIMER S, SMITH EB: Comparison of topical erythromycin 1. 5 percent solution versus topical clindamycin phosphate 1 percent solution in the treatment of acne vulgaris. Cutis (1982) 29:624, 628-632.
69. PUHVEL SM: Effects of treatment with erythromycin 1.5 percent topical solution or clindamycin phosphate 1.0 percent topical solution on P. acnes counts and free fatty acid levels. Cutis (1983) 31:339-342.
70. SHALITA AR, SMITH EB, BAUER E: Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison. Arch. Dermatol. (1984) 120:351-355.
71. LEYDEN JJ, SHALITA AR, SAATJIAN GD, SEFTON J: Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J. Am. Acad Dermatol. (1987) 16:822-827.
72. SWINYER LJ, BAKER MD, SWINYER TA, MILLS O Jr: A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br. J. Dermatol. (1988) 119:615-622.
73. SHALITA AR, SMITH JG, PARISH LC, SOFMAN MS, CHALKER DK: Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int. J. Dermatol. (1995) 34:434-437.
74. SCHACHNER L, PESTANA A, KITTLES C: A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J. Am. Acad Dermatol. (1990) 22:489-495.
75. LANGER A, SHEEHAM-DARE R, LAYTON A: A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac®) and erythromycin + zinc acetate (Zineryo®) in the treatment of mild to moderate facial acne vulgaris. J. Eur Acad. Dermatol Venereol. (2007) 21:311-319.
76. PACKMAN AM, BROWN RH, DUNLAP FE, KRAUS SJ, WEBSTER GF: Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. Int. J. Dermatol (1996) 35:209-211.
77. WEISS JW. SHAVIN J, DAVIS M: Preliminary results of a nonrandomized, multicenter, open-labcl study of patient satisfaction after treatment with combination benzoyl peroxide/clindamycin topical gel for mild to moderate acne. Clin. Ther. (2002) 24:1706-1717.
78. TUCKER SB, TAUSEND R, COCHRAN R, FLANNIGAN SA: Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br. J. Dermatol. (1984) 110:487-492.
79. TSCHEN EH, KATZ HI, JONES TM et al.: A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis (2001) 67:165-169.
80. ELLIS CN, LEYDEN J, KATZ HI et al.: Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis (2001) 67(2 suppl.): 13-20.
81. CUNLIFFE WJ, HOLLAND KT, BOJAR R, LEVY SF: A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin. Ther. (2002) 24:1117-1133.
82. RIETSCHEL RL, DUNCAN SH: Clindamycin phosphate use in combination with tretinoin in the treatment of acne. Int. J. Dermatol. (1983) 22:41-43.
83. RICHTER JR, FORSTROM LR, KIISTALA UO, JUNG EG: Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velace®) and a proprietary 0.025% tretinoin gel formulation (Aberela®) in the topical control of facial acne. J. Eur. Acad. Dermatol. Venereol. (1998) 11:227-233.
84. ZOUBOULIS CH C, DERUMEAUX L, DECROIX J, MACIEJEWSKA-UDZIELA B, CAMBAZARD F, STUHLERT A: A multicentrc, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac®) applied once daily and clindamycin lotion formulation (Dalacin T®) applied twice daily in the topical treatment of acne vulgaris. Br. J. Dermatol. (2000) 143:498-505.
85. LEYDEN JJ, KROCHMAL L, YAROSHINSKY A: Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J. Am. Acad. Dermatol. (2006) 54:73-81.
86. WOLF JE JR, KAPLAN D, KRAUS SJ et al.: Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J. Am. Acad. Dermatol. (2003) 49(Suppl.):S211-S217.
87. TANGHETTI E, ABRAMOVITS W, SOLOMON B, LOVEN K, SHALITA A: Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J. Drugs Dermatol. (2006) 5:256-261.
88. BOWMAN S, GOLD M, NASIR A, VAMVAKIAS G: Comparison of clindamycin/ benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J. Drugs Dermatol. (2005) 4:611-618.
89. ZHANG JZ, LI LF, TU YT, ZHENG J: A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J. Dermatol. Treat. (2004) 15:372-378.
90. FAGUNDES DS, FRASER JM, KLAUDA HC: New therapy update - a unique combination formulation in the treatment of inflammatory acne. Cutis (2003) 72(1 Suppl.):16-19.
91. LEYDEN JJ, BERGER RS, DUNLAP FE, ELLIS CN, CONNOLLY MA, LEVY SF: Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatment of acne vulgaris. Am. J. Clin. Dermatol. (2001) 2:33-39.
92. LEYDEN JJ, HICKMAN JG, JARRATT MT, STEWART DM, LEVY SF: The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J. Cutan. Med. Surg. (2001) 5:37-42.
93. STOUGHTON RB, RESH W: Topical clindamycin in the control of acne vulgaris. Cutis (1976) 17:551-554.
94. RAJKA G: On therapeutic approaches to some special types of acne. Acta Dermatovenerol. (1985) Suppl. 120:39-42.
95. CAMBAZARD F: Clinical efficacy of Velac®, a new tretinoin and clindamycin phosphate gel in acne vulgaris. J. Eur. Acad. Dermatol. Venereol. (1998) 11(Suppl. 1):S20-S27.
96. PARRY MF, RHA C-K: Pseudomembranous colitis caused by topical clindamycin phosphate. Arcb. Dermatol. (1986) 122:583-584.
97. MILSTONE EB, MCDONALD AJ, SCHOLHAMER CF: Pseudomembranous colitis after topical application of clindamycin. Arch. Dermatol. (1981) 117:154-155.
98. SCHIEDERMAYER DL, LOO FD: Topical clindamycin-associated diarrhea. Case report and review of the literature. Wisc. Med. J. (1987) 86(3):29-30.
99. COSKEY RJ: Contact dermatitis due to clindamycin. Arch. Dermatol. (1978) 114:446.
100. DEGROOT AC: Contact allergy to clindamycin. Contact Derm. (1982) 8:428.
101. YOKOYAMA R, MIZUNO E, TAKEUCHI M, ABE M, UEDA H: Contact dermatitis to clindamycin. Contact Derm. (1991) 25:125.
102. CONDE-SALAZAR L, GUIMARAENS D, ROMERO LV: Contact dermatitis from clindamycin. Contact Derm. (1983) 9:225.
103. SCISSORS B, SHWAYDER T: Topical clindamycin reproducibly causing tinnitus in a 14-year-old boy. J. Am. Acad. Dermatol. (2006) 54(5 Suppl.):S243-S244.
104. DOSIK JS, GILBERT RD, ARSONNAUD S: Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. Skin Med. (2006) 5:219-223.
105. BRAND B, GILBERT R, BAKER MD et al.: Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J. Am. Acad. Dermatol. (2003) 49(3 Suppl.):S227-S232.
106. ROTHMAN KF. POCHI PE: Use of oral and topical agents for acne in pregnancy. J. Am. Acad. Dermatol. (1988) 19:431-442.
107. WAUBEN-PENRIS PJJ, CERNEUS DP, VAN DEN HOVER WE, LEUVEN PJMJ, DEN BROK JHAM, HALL DWR: Immunomodulary effects of tretinoin in combination with clindamycin. J. Eur. Acad. Dermatol. Venerol. (1998) 11(Suppl. 1):S2-S7.
108. KELLETT N, WEST F, FINLAY AY: Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomized controlled trial. Br. J. Dermatol. (2006) 154:524-532.
109. HONZAK L, SENTJURC M: Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Eur. J. Physiol. (2000) 440(Suppl.):R44-R45.
110. SOLDO-BELIC A, CAJKOVAC V, VUJIC-PODLIPEC D et al.: Advantages of liposome-encapsulated 1% clindamycin solution versus 1% clindamycin solution in the therapy of acne vulgaris. Acta Dermatovenereol. Croat. (1999) 7:77-85.